Kathleen M Akgün1,2, Supriya Krishnan1,3, Adeel A Butt4,5,6, Cynthia L Gibert7, Christopher J Graber8, Laurence Huang9, Margaret A Pisani2, Maria C Rodriguez-Barradas10, Guy W Soo Hoo11, Amy C Justice1,2,12, Kristina Crothers13, Janet P Tate2,3. 1. Department of Medicine, VA Connecticut Healthcare System, West Haven. 2. Department of Internal Medicine, Yale University School of Medicine, New Haven. 3. VA Connecticut Healthcare System, West Haven, Connecticut. 4. Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, USA. 5. Weill Cornell Medical College, Doha, Quatar and New York, New York, USA. 6. Hamad Medical Corporation, Doha, Qatar. 7. Washington DC VA Medical Center, Washington, DC. 8. Infectious Diseases Section, and VA Greater Los Angeles Healthcare System and the Geffen School of Medicine at University of California, Los Angeles. 9. Department of Medicine, Zuckerberg San Francisco, General Hospital and University of California, San Francisco, California. 10. Infectious Diseases Section, Michael E. DeBakey VAMC and Department of Medicine, Baylor College of Medicine, Houston, Texas. 11. Pulmonary and Critical Care Section, VA Greater Los Angeles Healthcare System and Geffen School of Medicine at University of California, Los Angeles, California. 12. Yale School of Public Health, New Haven, Connecticut. 13. Department of Medicine, VA Puget Sound Healthcare System and University of Washington, Seattle, Washington, USA.
Abstract
BACKGROUND: People with HIV (PWH) with access to antiretroviral therapy (ART) experience excess morbidity and mortality compared with uninfected patients, particularly those with persistent viremia and without CD4+ cell recovery. We compared outcomes for medical intensive care unit (MICU) survivors with unsuppressed (>500 copies/ml) and suppressed (≤500 copies/ml) HIV-1 RNA and HIV-uninfected survivors, adjusting for CD4+ cell count. SETTING: We studied 4537 PWH [unsuppressed = 38%; suppressed = 62%; 72% Veterans Affairs-based (VA) and 10 531 (64% VA) uninfected Veterans who survived MICU admission after entering the Veterans Aging Cohort Study (VACS) between fiscal years 2001 and 2015. METHODS: Primary outcomes were all-cause 30-day and 6-month readmission and mortality, adjusted for demographics, CD4+ cell category (≥350 (reference); 200-349; 50-199; <50), comorbidity and prior healthcare utilization using proportional hazards models. We also adjusted for severity of illness using discharge VACS Index (VI) 2.0 among VA-based survivors. RESULTS: In adjusted models, CD4+ categories <350 cells/μl were associated with increased risk for both outcomes up to 6 months, and risk increased with lower CD4+ categories (e.g. 6-month mortality CD4+ 200-349 hazard ratio [HR] = 1.35 [1.12-1.63]; CD4+ <50 HR = 2.14 [1.72-2.66]); unsuppressed status was not associated with outcomes. After adjusting for VI in models stratified by HIV, VI quintiles were strongly associated with both outcomes at both time points. CONCLUSION: PWH who survive MICU admissions are at increased risk for worse outcomes compared with uninfected, especially those without CD4+ cell recovery. Severity of illness at discharge is the strongest predictor for outcomes regardless of HIV status. Strategies including intensive case management for HIV-specific and general organ dysfunction may improve outcomes for MICU survivors.
BACKGROUND: People with HIV (PWH) with access to antiretroviral therapy (ART) experience excess morbidity and mortality compared with uninfected patients, particularly those with persistent viremia and without CD4+ cell recovery. We compared outcomes for medical intensive care unit (MICU) survivors with unsuppressed (>500 copies/ml) and suppressed (≤500 copies/ml) HIV-1 RNA and HIV-uninfected survivors, adjusting for CD4+ cell count. SETTING: We studied 4537 PWH [unsuppressed = 38%; suppressed = 62%; 72% Veterans Affairs-based (VA) and 10 531 (64% VA) uninfected Veterans who survived MICU admission after entering the Veterans Aging Cohort Study (VACS) between fiscal years 2001 and 2015. METHODS: Primary outcomes were all-cause 30-day and 6-month readmission and mortality, adjusted for demographics, CD4+ cell category (≥350 (reference); 200-349; 50-199; <50), comorbidity and prior healthcare utilization using proportional hazards models. We also adjusted for severity of illness using discharge VACS Index (VI) 2.0 among VA-based survivors. RESULTS: In adjusted models, CD4+ categories <350 cells/μl were associated with increased risk for both outcomes up to 6 months, and risk increased with lower CD4+ categories (e.g. 6-month mortality CD4+ 200-349 hazard ratio [HR] = 1.35 [1.12-1.63]; CD4+ <50 HR = 2.14 [1.72-2.66]); unsuppressed status was not associated with outcomes. After adjusting for VI in models stratified by HIV, VI quintiles were strongly associated with both outcomes at both time points. CONCLUSION: PWH who survive MICU admissions are at increased risk for worse outcomes compared with uninfected, especially those without CD4+ cell recovery. Severity of illness at discharge is the strongest predictor for outcomes regardless of HIV status. Strategies including intensive case management for HIV-specific and general organ dysfunction may improve outcomes for MICU survivors.
Authors: Ank E Nijhawan; Lisa R Metsch; Song Zhang; Daniel J Feaster; Lauren Gooden; Mamta K Jain; Robrina Walker; Shannon Huffaker; Michael J Mugavero; Petra Jacobs; Wendy S Armstrong; Eric S Daar; Meg Sullivan; Carlos Del Rio; Ethan A Halm Journal: J Acquir Immune Defic Syndr Date: 2019-03-01 Impact factor: 3.731
Authors: Kathleen M Akgün; Janet P Tate; Kristina Crothers; Stephen Crystal; David A Leaf; Julie Womack; Todd T Brown; Amy C Justice; Krisann K Oursler Journal: J Acquir Immune Defic Syndr Date: 2014-12-01 Impact factor: 3.731
Authors: François Barbier; Antoine Roux; Emmanuel Canet; Patricia Martel-Samb; Philippe Aegerter; Michel Wolff; Bertrand Guidet; Elie Azoulay Journal: Intensive Care Med Date: 2014-09-19 Impact factor: 17.440
Authors: Christopher Rentsch; Janet P Tate; Kathleen M Akgün; Stephen Crystal; Karen H Wang; S Ryan Greysen; Emily A Wang; Kendall J Bryant; David A Fiellin; Amy C Justice; David Rimland Journal: AIDS Behav Date: 2016-03
Authors: A Adlakha; M Pavlou; D A Walker; A J Copas; N Dufty; S Batson; S G Edwards; M Singer; R F Miller Journal: Int J STD AIDS Date: 2011-09 Impact factor: 1.359
Authors: Shawn L Fultz; Melissa Skanderson; Larry A Mole; Neel Gandhi; Kendall Bryant; Stephen Crystal; Amy C Justice Journal: Med Care Date: 2006-08 Impact factor: 2.983
Authors: Nazir I Lone; Michael A Gillies; Catriona Haddow; Richard Dobbie; Kathryn M Rowan; Sarah H Wild; Gordon D Murray; Timothy S Walsh Journal: Am J Respir Crit Care Med Date: 2016-07-15 Impact factor: 21.405